Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05475821 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05475821 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 24 participants.
The verdict
NCT05475821, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will assess how safe ABBV-990 is and how ABBV-990 moves through the body of adult healthy participants. Adverse Events will be assessed. ABBV-990 is an investigational drug being developed for the treatment of SARS-CoV-2 infections. Participants are randomly assigned to one of the 5 treatment groups. Each group receives different treatment. There is 1 in 4 chance that participants are assigned to placebo. Approximately 40 adult healthy volunteers will be enrolled in a single site in the United States. Participants will receive oral tablet of ABBV-990 or matching placebo on Day 1 and followed for approximately 30 days. Participants will be confined for 5 days. Adverse Events and blood tests will be performed.
Interventions
- DRUG ABBV-990
- DRUG Placebo for ABBV-990
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2022-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05475821
The ClinicalTrials.gov registry entry for NCT05475821 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABBV-990 is the first listed.
NCT05475821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05475821 about?
NCT05475821 is a clinical study titled "Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants". This study will assess how safe ABBV-990 is and how ABBV-990 moves through the body of adult healthy participants. Adverse Events will be assessed. ABBV-990 is an investigational drug being developed for the treatment of SARS-CoV-2 infections. Participants are randomly assigned to one of the 5 trea...
What is the current status of trial NCT05475821?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-07-25. Estimated completion is 2022-09-26.
What interventions are being tested in trial NCT05475821?
The interventions under investigation include: ABBV-990 (DRUG), Placebo for ABBV-990 (DRUG).
Who is sponsoring clinical trial NCT05475821?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.